AstraZeneca’s Breast-Cancer Candidate Drug Loses FDA Panel Vote

The British pharmaceutical radical said it would proceed to enactment with U.S. regulators connected a reappraisal of its breast-cancer campaigner aft the cause failed to get backing astatine a cardinal advisory committee vote.